

Drugs for the treatment of pulmonary arterial hypertension
<http://www.nice.org.uk/guidance/index.jsp?action=byID&o=11708>

Dear Consultees and commentators,

Last year NICE consulted with stakeholders about a possible change of remit and scope for this technology appraisal.

In response, a significant number of commentators were of the view that NICE could not add value by continuing its appraisal. This was because NHS specialised commissioners have now put in place agreed arrangements for the supply of targeted therapies for all patients affected at the most severe stages of the condition. The Institute discussed the result of this consultation with the Department of Health (DH) and Ministers have agreed that this topic should be removed from the work programme.

We will announce this on our website on Monday 6th April. If you have any questions, please contact the project manager for this appraisal, Jeremy Powell on 020 7045 2248 or at jeremy.powell@nice.org.uk.

Yours sincerely,

Dr Carole Longson
Director, Centre for Health Technology Evaluation